Ken Paxton accuses the three big insulin manufacturers of conspiring with the three largest pharmacy companies to overcharge patients hundreds of dollars per dose while raking in sizable profits.
Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.
Novo Nordisk CEO Lars Fruergaard Jorgensen has called attention to the complexities of the U.S. healthcare system while ...